Identification of differentially expressed microRNA in parathyroid tumors

Annals of Surgical Oncology

Volumn 18, Issue 4, 2011, Pages 1158-1165

  Rahbari, Reza ^a   Holloway, Alisha K ^b   He, Mei ^a   Khanafshar, Elham ^c   Clark, Orlo H ^c   Kebebew, Electron ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MIR 126; MIR 26B; MIR 30B; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CLUSTER ANALYSIS; GENE EXPRESSION; HUMAN; HUMAN TISSUE; PARATHYROID ADENOMA; PARATHYROID CARCINOMA; PARATHYROID HYPERPLASIA; PARATHYROID TUMOR;

ADENOMA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERPLASIA; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARATHYROID GLANDS; PARATHYROID NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 79955869039     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-1359-7     Document Type: Article

References (33)

1. Kebebew E, Clark OH. Parathyroid adenoma, hyperplasia, and carcinoma: localization, technical details of primary neck exploration, and treatment of hypercalcemic crisis. Surg Oncol Clin North Am. 1998;7(4):721-48. (Pubitemid 28436537)
2. Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet. 2002;32(4):676-80. (Pubitemid 35435184)
3. Fernandez-Ranvier GG, Khanafshar E, Tacha D, et al. Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer. 2009;115(2):334-44.
4. Haven CJ, Howell VM, Eilers PH, et al. Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Res. 2004; 64(20):7405-11. (Pubitemid 39372081)
5. Fujimoto Y, Obara T. How to recognize and treat parathyroid carcinoma. Surg Clin North Am. 1987;67(2):343-57.
6. Schantz A, Castleman B. Parathyroid carcinoma. A study of 70 cases. Cancer. 1973;31(3):600-5.
7. Shattuck TM, Valimaki S, Obara T, et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003;349(18):1722-9. (Pubitemid 37315009)
8. Mallya SM, Arnold A. Cyclin D1 in parathyroid disease. Front Biosci. 2000;5:D367-71.
9. Yano S, Sugimoto T, Tsukamoto T, et al. Decrease in vitamin D receptor and calcium-sensing receptor in highly proliferative parathyroid adenomas. Eur J Endocrinol. 2003;148(4):403-11. (Pubitemid 36527411)
10. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009;27(34):5848-56.
11. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-54. (Pubitemid 24014542)
12. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-97.
13. Lagana A, Forte S, Giudice A, et al. miRo: a miRNA knowledge base. Database (Oxford). 2009; 2009:bap008.
14. Smyth GK, Speed T. Normalization of cDNA microarray data. Methods: 2003;31(4):265-73. (Pubitemid 37338763)
15. Yang YH, Dudoit S, Luu P, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 2002;30(4):e15.
16. Smyth G. limma: linear models for microarray data. In: Gentleman R, Irizarry RA, Dudoit S, editors. Bioinformatics and computational biology solutions using R and Bioconductor. New York: Springer; 2005. p 397-420.
17. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004; 3:Article3.
18. Lee PK, Jarosek SL, Virnig BA, et al. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007;109(9):1736-41. (Pubitemid 46668534)
19. Kebebew E, Arici C, Duh QY, Clark OH. Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg. 2001;136(8):878-85. (Pubitemid 32729547)
20. Howell VM, Gill A, Clarkson A, et al. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab. 2009;94(2):434-41.
21. Cetani F, Ambrogini E, Viacava P, et al. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol. 2007;156(5):547-54. (Pubitemid 46796521)
22. Corbetta S, Vaira V, Guarnieri V, et al. Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Endocr Relat Cancer. 2010;17(1): 135-46.
23. Kytola S, Farnebo F, Obara T, et al. Patterns of chromosomal imbalances in parathyroid carcinomas. Am J Pathol. 2000;157(2): 579-86. (Pubitemid 30626916)
24. Lu Y, Ryan SL, Elliott DJ, et al. Amplification and overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in medulloblastoma. PLoS One. 2009;4(7):e6159.
25. Guled M, Lahti L, Lindholm PM, et al. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis. Genes Chromosomes Cancer. 2009;48(7):615-23.
26. Jardin F, Callanan M, Penther D, et al. Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4 ? CD56 ? haematodermic neoplasms and contribute to the aggressiveness of the disease. Leukemia. 2009;23(4):698-707.
27. Zanette DL, Rivadavia F, Molfetta GA, et al. miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz J Med Biol Res. 2007;40(11):1435-40. (Pubitemid 350302855)
28. Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009; 361(15):1437-47.
29. Liu X, Chen Z, Yu J, et al. MicroRNA Profiling and head and neck cancer. Comp Funct Genomics. 2009:837514.
30. Liu B, Peng XC, Zheng XL, et al. MiR-126 restoration downregulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer. 2009;66(2):169-75.
31. Sun Y, Bai Y, Zhang F, et al. miR-126 inhibits non-small cell lung cancer cells proliferation by targeting EGFL7. Biochem Biophys Res Commun. 2010;391(3):1483-9.
32. Guo C, Sah JF, Beard L, et al. The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer. 2008;47(11):939-46.
33. Hussein K, Dralle W, Theophile K, et al. Megakaryocytic expression of miRNA 10a, 17-5p, 20a and 126 in Philadelphia chromosome-negative myeloproliferative neoplasm. Ann Hematol. 2009;88(4):325-32.